Community-acquired pneumonia
First line
Clarithromycin is included in empirical regimens for community-acquired pneumonia in outpatient adults without comorbidities and risk factors for drug-resistant pneumococci. /ATS 2019 recommend macrolide monotherapy where regional S. pneumoniae macrolide resistance is below 25%. For inpatients the macrolide is combined with a beta-lactam. The 2018 Cochrane review confirms comparable efficacy of macrolides and beta-lactams in the outpatient group.
In regions with S. pneumoniae macrolide resistance above 25% monotherapy is not used. In Russia, monitoring data from 2022 show that several cities exceed this threshold – clinicians rely on local resistance maps.